{"id":525687,"date":"2010-04-13T08:01:44","date_gmt":"2010-04-13T12:01:44","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=73040"},"modified":"2010-04-13T08:01:44","modified_gmt":"2010-04-13T12:01:44","slug":"alkermes-files-drug-app-with-fda","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/525687","title":{"rendered":"Alkermes Files Drug App With FDA"},"content":{"rendered":"\n
Biotech<\/a>, Drugs<\/a>, FDA<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Alkermes (NASDAQ: ALKS<\/a>), the Waltham, MA-based biotech company, is announcing today it has filed an application with the FDA to start marketing a long-lasting version of naltrexone (Vivitrol) for people who are addicted to opioid-based narcotics. The Alkermes treatment, a once-monthly injection, is already approved by the FDA for treating alcohol dependence. Alkermes has asked the FDA for a faster-than-usual six-month review of its new application.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Drugs, FDA Luke Timmerman wrote: Alkermes (NASDAQ: ALKS), the Waltham, MA-based biotech company, is announcing today it has filed an application with the FDA to start marketing a long-lasting version of naltrexone (Vivitrol) for people who are addicted to opioid-based narcotics. The Alkermes treatment, a once-monthly injection, is already approved by the FDA for […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-525687","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/525687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=525687"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/525687\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=525687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=525687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=525687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}